Eric F. Morand Grant/research support from: AstraZeneca, Consultant of: AstraZeneca, Speakers bureau: AstraZeneca

**AB0385** TARGETING CD38 IN SYSTEMIC LUPUS ERYTHEMATOSUS

L. Ostendorf1,2, U. Schneider1, M. Urbich1, P. Enghard3,4, F. Heinrich2, P. Durek5, G. Hertl6, H. Miescher7, M. F. Marschner8, G. R. Burmeister9, A. Radbruch1, F. H. Hiepe1,2, T. Alexander1,2,3,4,5.

1Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany; 2Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany; 3Charité – Universitätsmedizin Berlin, Department of Nephrology, Berlin, Germany

**Background:** Depletion of long-lived plasma cells (PC) resembles a novel concept for the treatment of antibody-mediated autoimmune diseases, such as systemic lupus erythematosus (SLE). Therapeutic approaches such as autologous stem-cell transplantation and proteasome inhibition are limited by significant treatment-related toxicity. A novel target for PC depletion is CD38, a surface protein that is highly expressed on plasma cells (PCs) but also activated T cells and most myeloid cells. Daratumumab is a monoclonal antibody targeting CD38 that is licensed for the treatment of multiple myeloma.

**Objectives:** Here, we aimed to ascertain clinical safety and efficacy of Daratumumab for the treatment of refractory SLE, as well as to gain insights into effects of Daratumumab on the immune system.

**Methods:** We treated two SLE patients with life- and organ-threatening SLE with four weekly dosis of 16 mg/kg Daratumumab. We performed integrative analyses of clinical, serological and immunological effects over a follow-up period of 6 months. Using flow cytometry and single-cell RNA and T-cell receptor sequencing we followed CD38 expression and composition of peripheral blood leukocytes with a special focus on memory T cells.

**Results:** Patient 1, a 50-year-old woman, suffered from active biopsy-proven class III lupus nephritis (LN) with nephrotic syndrome, pericarditis, arthritis and skin rash. Upon Daratumumab treatment, her glomerular filtration rate normalized within 3 months and proteinuria gradually declined from 6.4 to 1.9 g/24h Creatinine during the 120-day follow-up period. Pericarditis, arthritis and skin rash completely resolved. Patient 2, a 32-year-old woman, presented with autoimmune hemolytic anemia requiring blood transfusions, immune thrombocytopenia and cutaneous vasculitis. Her direct antiglobulin test normalized within 3 months and proteinuria gradually declined from 6.4 to 1.9 g/24h Creatinine during the 120-day follow-up period. Pericarditis, arthritis and skin rash completely resolved. They presented levels of serum creatinine ≤1.2 mg/dl (or decrease to initial values) and creatinine ≥1.2 mg/dl. Proteinuria ≤0.5 g/24h and inactive sediment. A quantitative descriptive analysis has been carried out with the statistical program IBM SPSS 24.0 for Windows.

**Results:** Thirteen patients (11 women and 2 men) were included, with a mean age of 32.3 years and a mean follow-up time from the start of RTX of 11.09 years. Class IV NL was the most frequent (46.15%), followed by Class III NL (38.46%). Class V NL represented 76.9% and another 76.9% the combination of Class III-V. Renal failure was present in 46.2% of patients at the beginning of RTX, 8.46% hematuria and all patients presented proteinuria, of which 76.9% were confirmed to have nephrotic range and 84.6% showed hypoalbuminemia. With regard to previous treatments, all cases had received high-dose of GC and at least one immunosuppressant: 92.3% had failed to CF, a similar percentage had received azathioprine and 46.2% had failed to mycophenolate. After treatment with RTX, partial or complete response was achieved in 84.61%, infections were identified in 46.15% of patients and allergic reactions in 15.39%; no adverse events were mild and all cases developed favorably.

**Conclusion:** RTX treatment is effective in SLE and specifically in LN. More than 80% of patients in our study with refractory LN benefitted from RTX treatment. Despite the not insignificant incidence of adverse events, most were mild and resolved without sequelae or complications, so we can conclude that the safety of RTX is acceptable and should be considered as a treatment option for these patients according to the good risk-benefit profile.

**Disclosure of Interests:** Consuelo Ramos Giráldez: None declared, Maria Luisa Velloso Feijoo: None declared, Sergio Rodríguez Montero: None declared, José Luis Marenco Speakers bureau: AbbVie, Pfizer, Lilly

**DOI:** 10.1136/annrheumdis-2020-eular.4305

**AB0386** TREATMENT STATUS FOR OSTEOPOROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: CROSS-SECTIONAL ANALYSIS FROM A LUPUS REGISTRY OF NATIONWIDE INSTITUTIONS (LUNA)

C. Ramos Giráldez1, M. L. Velloso Feijoo2, S. Rodríguez Montero1, J. L. Marenco3, Hospital Valme, Rheumatology Unit, Valme Hospital, Seville, Spain; 4Hospital Valme, Rheumatology Unit, Valme Hospital, Seville, Spain; 5Hospital Valme, Rheumatology Unit, Valme Hospital, Seville, Spain; 6Hospital Valme, Rheumatology Unit, Valme Hospital, Seville, Spain

**Background:** Osteoporosis is one of the most important adverse effects of glucocorticoids in patients with systemic lupus erythematosus (SLE). Because osteoporosis is accelerated by chronic kidney disease (CKD), more attention should be paid to the treatment for osteoporosis in SLE patients with CKD. Many treatment options for osteoporosis have emerged recently, but treatment status in patients with SLE is not elucidated.

**Objectives:** The purpose of this study is to elucidate the treatment status for osteoporosis in patients with SLE among the CKD stages.

**Methods:** Using data from a lupus registry of nationwide institutions (LUNA), a cross-sectional analysis was performed. We firstly described treatment status for osteoporosis in all enrolled patients. Secondary, treatment status for osteoporosis was compared among CKD stages. Finally, bone damage in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) was compared among CKD stages.

**Results:** SDI was the highest in patients with CKD stage 3. The percentage of osteoporosis (WHO) of enrolled 917 patients was 44 (34-57) years and 809 patients (88%) were female. CKD stages were: CKD stage 1, 234 (26%); CKD stage 2, 465 (51%); CKD stage 3, 189 (21%); CKD stage 4, 9 (1%); CKD stage 5, 16 (2%). Mean (IQR) age, female sex,